DNA X, Inc. (SONM) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -101.48%, forward earnings yield 625.00%.
Criteria proven by this page:
Overall SharesGrow Score: 35/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -13.2 | 0.00 | -11.84 | 1.91 | - |
| 2018 | 76.8 | -0.93 | 19.13 | 0.72 | - |
| 2019 | -47.1 | 1.02 | 47.62 | 10.46 | - |
| 2020 | -20.1 | 0.38 | 21.20 | 9.41 | - |
| 2021 | -4.1 | 0.11 | 8.43 | 2.88 | - |
| 2022 | -15.7 | 0.18 | 11.03 | 3.16 | - |
| 2023 | -6,303.0 | 63.30 | 25.36 | 6.06 | - |
| 2024 | -8.0 | 0.00 | -47.08 | 4.60 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-4.37 | $59.03M | $-8.52M | -14.4% |
| 2018 | $0.65 | $135.67M | $1.28M | 0.9% |
| 2019 | $-13.89 | $116.25M | $-25.83M | -22.2% |
| 2020 | $-6.48 | $63.99M | $-29.93M | -46.8% |
| 2021 | $-4.08 | $54.57M | $-38.63M | -70.8% |
| 2022 | $-0.49 | $69.83M | $-14.09M | -20.2% |
| 2023 | $-0.02 | $93.63M | $-90K | -0.1% |
| 2024 | $-7.13 | $58.3M | $-33.65M | -57.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $19.98 | $19.98 – $19.98 | $143.2M | $143.2M – $143.2M | 1 |
